Filing Flows › Health Care › Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals (AUPH) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 30, 2026 · Aurinia Pharmaceuticals (AUPH) Q3 2026 earnings results →
Q3 2026 Revenue up 14% year over year to $83.7M · 38¢ of every $1 of revenue kept as net profit · operating margin 42.3%
Aurinia Pharmaceuticals made $83.7M in Q3 2026 (+14% Y/Y): Net product sales $79.4M, License, collaboration and royalty revenue $4.3M. Operating margin 42.3%, net earnings $31.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 30, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $83.7M in Q3 2026, up 14% year over year and up 1% from the previous quarter. Net product sales was the largest line at 95% of revenue. Net product sales added $8.8M year over year (up 12%), 86% of the total change.
Operating profit was $35.4M, a 42.3% margin (up 1.8 points year over year). Of the extra revenue versus Q3 2025, 55% reached operating profit, above the 40% margin then. Total costs grew 11% against revenue growth of 14%. Net earnings were $31.7M, roughly flat year over year. The effective tax rate was 18.1%.
Operating cash flow was $46.4M (up 4% year over year), 146% of net earnings. Non-cash charges added back $4.8M of depreciation and amortization and $6.1M of share-based compensation. Working capital and other items added $3.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 30, 2026 | $83.7M | +14% | 42.3% | $31.7M | $46.4M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $83.2M | +19% | 55.7% | $37.4M | $52.6M |
| Q1 2026 | 10-Q | May 7, 2026 | $77.7M | +24% | 53.3% | $34.4M | $32.6M |
| Q4 2025 | 10-K | Feb 26, 2026 | $77.1M | +29% | 43.1% | $211M | $45.7M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $73.5M | +8% | 40.5% | $31.6M | $44.4M |
| Q2 2025 | 10-Q | Jul 31, 2025 | $70.0M | +22% | 28.7% | $21.5M | $44.2M |
| Q1 2025 | 10-Q | May 12, 2025 | $62.5M | +24% | 35.0% | $23.3M | $1.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Aurinia Pharmaceuticals
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for the potential treatment of autoimmune diseases. Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States (“U.S.”), and Aurinia sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), for the European and Japanese market.
In its own words, from its 10-K, filed Feb 26, 2026.
Aurinia Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +14% against the peers' median +10%. Operating margin: 42.3% against the peers' median 30.7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AUPH Aurinia Pharmaceuticals | Q3 2026 | $83.7M | +14% | 42.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Aurinia Pharmaceuticals 10-Q on SEC EDGAR · CIK 1600620 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns AUPH and who is buying
More on AUPH
- How Aurinia Pharmaceuticals makes money: revenue by segment
- Aurinia Pharmaceuticals next earnings date and what analysts expect
- Aurinia Pharmaceuticals stock forecast, price target and fair value
- Who owns Aurinia Pharmaceuticals stock: holders, funds and Congress trades
- Aurinia Pharmaceuticals guidance and outlook
- Is Aurinia Pharmaceuticals a takeover target? LBO and rumors
- Aurinia Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Aurinia Pharmaceuticals guidance history: guided vs reported
- Aurinia Pharmaceuticals operating margin by quarter
- Aurinia Pharmaceuticals net income by quarter
- Aurinia Pharmaceuticals R&D spending by quarter
- Aurinia Pharmaceuticals Net product sales revenue by quarter
- Aurinia Pharmaceuticals License, collaboration and royalty revenue revenue by quarter
Compare AUPH with
- Aurinia Pharmaceuticals vs Rhythm Pharmaceuticals (AUPH vs RYTM)
- Aurinia Pharmaceuticals vs UroGen Pharma (AUPH vs URGN)
- Aurinia Pharmaceuticals vs Phathom Pharmaceuticals (AUPH vs PHAT)
- Aurinia Pharmaceuticals vs Syndax Pharmaceuticals (AUPH vs SNDX)
- Aurinia Pharmaceuticals vs Rigel Pharmaceuticals (AUPH vs RIGL)